SummaryRMgm-4831
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 32379764 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei NK65 |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Briquet S, Vaquero C |
Name Group/Department | Sorbonne Universités |
Name Institute | Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris) |
City | Paris |
Country | France |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-4831 |
Principal name | Δhmgb2 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Reduced growth of blood stages and C57Bl/6 are able to clear the infection after day 15 (in contrast to wild type infections where mice die from hyperparasitemia) |
Gametocyte/Gamete | Not tested |
Fertilization and ookinete | Not tested |
Oocyst | Not tested |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation See also RMgm-1251 for a P. berghei ANKA mutant (from the same group) lacking expression of HMGB2 (with reduced cerebral complications in C57Bl/6 mice) See also RMgm-162 for a P. yoelii mutant lacking expression of HMGB2. These parasites showed a slightly reduced growth rate of blood stages and reduced ookinete and oocyst production. |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0712900 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0817900 | ||||||||||||||||||||||||
Gene product | high mobility group protein B2 | ||||||||||||||||||||||||
Gene product: Alternative name | HMGB2 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | Two PCR fragments flanking the HMGB2 open reading frame (ORF) were amplified from the genomic DNA using oligonucleotides listed in Supplementary Table S1. Amplification of the 5’ untranslated region (UTR) with the primer combination 5’-hmgb2-for and 5’-hmgb2-rev including ApaI and SmaI restriction sites, respectively resulted in a 526-bp fragment and was cloned upstream to the positive selection marker human dihydrofolate reductase (hudhfr) previously introduced into the pBC SK- vector (Stratagene) under the control of EF1α promoter and of dhrf/ts 3’UTR (dihydrofolate reductase/thymidylate synthase). Next, the 3’UTR region was amplified with 3’-hmgb2-for and 3’-hmgb2-rev primers including NotI and AscI restriction sites. This fragment was inserted downstream to the hudhrf box resulting in the hmgb2 targeting vector pBC-5’B2hudhfr3’B2 allowing replacement of the endogenous hmgb2 locus in PbANKA upon a double cross-over homologous recombination and subsequent selection with the antifolate pyrimethamine. P. berghei parasite transfections were performed with 5 μg ApaI/AscI-digested pBC-5’B2hudhfr3’B2. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
![]()
| |||||||||||||||||||||||||
top of page |